Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
Authors:
Open Access
- 1 April 2003
- journal article
- clinical trial
- Published by Wiley in HIV Medicine
- Vol. 4 (2) , 94-100
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjectsHIV Medicine, 2002
- Simplifying Protease Inhibitor Therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Clinical perspectives on HIV-associated lipodystrophy syndrome: an updateAIDS, 2001
- Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationBritish Journal of Clinical Pharmacology, 2001
- Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapyAIDS, 1999
- Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)AIDS, 1999
- Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patientsAIDS, 1998
- Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*Clinical Pharmacology & Therapeutics, 1998
- RitonavirClinical Pharmacokinetics, 1998
- Quantification of the anti‐HIV drug saquinavir by high‐speed on‐line high‐performance liquid chromatography/tandem mass spectrometryJournal of Mass Spectrometry, 1995